A5003749712- Genomics and Chromatin Dynamics
- RNA Research and Splicing
- Developmental Biology and Gene Regulation
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related gene regulation
- Forensic Toxicology and Drug Analysis
- Synthesis and properties of polymers
- Microfluidic and Capillary Electrophoresis Applications
- Analytical Chemistry and Chromatography
- Protein purification and stability
- RNA modifications and cancer
- Epigenetics and DNA Methylation
University of Cincinnati
2014-2019
University of Cincinnati Medical Center
2016-2017
The transcriptional shift from repression to activation of target genes is crucial for the fidelity Notch responses through incompletely understood mechanisms that likely involve chromatin-based control. To activate silenced genes, repressive chromatin marks are removed and active must be acquired. Histone H3 lysine-4 (H3K4) demethylases key modifiers establish state at genes. However, counteracting histone methyltransferase required remained elusive. Here, we show RBP-J interacting factor...
Notch is a conserved signaling pathway that specifies cell fates in metazoans. Receptor-ligand interactions induce changes gene expression, which regulated by the transcription factor CBF1/Su(H)/Lag-1 (CSL). CSL interacts with coregulators to repress and activate from target genes. While molecular details of activator complex are relatively well understood, structure-function CSL-mediated repressor complexes poorly defined. In Drosophila, antagonist Hairless directly binds Su(H) (the fly...
The Notch pathway is a cell-to-cell signaling mechanism that essential for tissue development and maintenance, aberrant has been implicated in various cancers, congenital defects, cardiovascular diseases. activates the expression of target genes, which are regulated by transcription factor CSL (CBF1/RBP-J, Su(H), Lag-1). interacts with both transcriptional corepressor coactivator proteins, functioning as repressor activator, respectively. Although activation complexes relatively well...
A high-affinity anti-cocaine monoclonal antibody, designated h2E2, is entering phase 1 clinical trials for cocaine abuse therapy. To gain insight into the molecular details of its structure that are important binding and metabolites, Fab fragment was generated crystallized with without ligand. Structures unliganded bound to benzoylecgonine were determined, compared each other antibodies. The affinity h2E2 antibody 4 n M , while metabolite 20 . Both higher than reported two previously...